Sichenzia Ross Ference LLP Represents Medicine Man Technologies, Inc. in Private Placement Offering of up to $14 Million
Press Release – New York, NY – June 10, 2019 – Sichenzia Ross Ference LLP announced today that it has represented Medicine Man Technologies, Inc. (OTC: MDCL) (“Medicine Man or the “Company”) in a securities purchase agreement with Dye Capital & Co. for the sale of up to $14 million of shares and common stock purchase warrants of the Company. The shares were sold at a price of $2.00 per share.
The warrants are exercisable for three years at an exercise price of $3.50. The securities purchase agreement provides for the sale of the shares in tranches with an initial closing held on June 6, 2019. At the initial closing, the Company issued and sold 1,500,000 shares of common stock and warrants to purchase 1,500,000 shares of common stock, for gross proceeds of $3,000,000.
Denver, Colorado based Medicine Man, is a fully integrated operator in the cannabis industry, offering consulting, retail pharma-grade products, and turnkey solutions for cannabis cultivators for over a decade. Medicine Man is leveraging its expertise and intellectual property to vertically integrate retail, cultivation, formulation, and distribution operations. The Company’s client portfolio includes active and past clients in 18 states and seven countries. The Company has recently announced the entry into binding term sheets to acquire, MedPharm Holdings, Medicine Man Dence, Los Sueños Farms and Mesa Organics on the heels of the signing of six cannabis related bills, including HB-19-1090 passed into law by the Colorado legislature on May 29, 2019.
The Sichenzia Ross Ference team was led by Partners Gregory Sichenzia and Marcelle Balcombe and associate Jacob Tabman.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Sichenzia Ross Ference LLP Represents Beyond Air, Inc. in a $11.5 Million Underwritten Public Offering of Common Stock and Concurrent Private Placement - December 13, 2019
- Sichenzia Ross Ference LLP Represents Relmada Therapeutics, Inc. in a $115 Million Underwritten Public Offering of Common Stock - December 6, 2019
- Sichenzia Ross Ference Trust & Estate Attorneys Quoted in LegalZoom Article - December 6, 2019